Kiniksa Pharmaceuticals International, plc (KNSA): Total Assets
$763.63M
As of 2025-12-31
$825.28M
As of 2026-03-31
+18.4%
3-year compound annual growth
+16.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $763.63M | +31.5% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $580.55M | +10.3% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $526.32M | +14.5% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $459.67M | +97.5% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $232.80M | -33.4% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $349.46M | +37.3% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $254.53M | -20.9% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $321.96M | +577.9% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $47.49M | n/a | 2019-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $763.63M | +31.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.53B | +1.9% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.45B | +6.2% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $689.80M | +21.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $1.63B | +3.3% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $1.26B | -18.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $1.32B | -5.1% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $1.06B | +84.1% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $1.93B | -12.2% |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗